Aptagen, LLC
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
Chimeric
Human matrix metalloprotease 9 (hMMP-9)
Protein
20 nM (reported value)
SP buffer: 50 mM Tris HCl, pH 7.4, 50 mM NaCl, 100 mM KCl, 5 mM CaCl2, 1 mM Magnesium Acetate.
23°C
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
Labels: Grade I Pilocytic astrocytoma, Grade I Meningioma, Grade II Astrocytoma, Grade II Ependymoma, Grade III Anaplastic astrocytoma, Grade IV Glioblastoma, Grade IV medulloblastoma, Grade IV lymphoma. Does not label healthy brain tissue.
This aptamer is a truncated and modified version of FB3
Human Matrix Metalloprotease 9 (hMMP-9) (F3Bomf) (ID# 378)
5'fUpmGpfCpfCpfCpfUpmGpfCpfCpfCpfUpfCpmApfCpfCpfCpmGpfUpfUpmApmGpfCpfCpfUpmGpmApmGpfCpmGpfCpfCpfCpfCpmGpfCpmAp3'
36
11563.12 g/mole
311900 L/(mole·cm)
72.22%
3.21
37.07
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
S Gomes et al. A 99mTc-MAG3-aptamer for imaging human tumours associated with high level of matrix metalloproteinase-9. Bioconjugate Chem. (2012). Accepted for print. DOI: 10.1021/bc300146c.
Have your aptamer oligo synthesized ORDER NOW
We are always looking for ways to improve. Please tell us what you think.